New drug combo tested for Tough-to-Treat uterine cancer
NCT ID NCT05106127
Summary
This study aims to check if adding a repurposed drug called EG-007 to the standard two-drug combination (lenvatinib and pembrolizumab) is safe for women with advanced endometrial cancer that has returned after chemotherapy. It will enroll about 28 women whose cancer is not a specific genetic type (MSI-H/dMMR). The main goal is to monitor side effects and see if patients can tolerate the three-drug combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.